Russell Investments Group Ltd. boosted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1,815.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,437 shares of the company's stock after acquiring an additional 18,422 shares during the period. Russell Investments Group Ltd.'s holdings in Axsome Therapeutics were worth $1,645,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at $52,000. R Squared Ltd acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $64,000. KBC Group NV lifted its holdings in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the period. Xponance Inc. boosted its position in shares of Axsome Therapeutics by 11.6% during the 4th quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after acquiring an additional 277 shares in the last quarter. Finally, Intrust Bank NA raised its position in Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after purchasing an additional 183 shares in the last quarter. Institutional investors own 81.49% of the company's stock.
Analyst Ratings Changes
AXSM has been the topic of several recent analyst reports. Morgan Stanley boosted their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective on the stock. Bank of America lifted their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, William Blair restated an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $169.80.
View Our Latest Report on AXSM
Insider Activity at Axsome Therapeutics
In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.40% of the stock is currently owned by corporate insiders.
Axsome Therapeutics Trading Up 0.3 %
Shares of AXSM traded up $0.27 on Wednesday, reaching $104.09. 313,315 shares of the company's stock were exchanged, compared to its average volume of 679,955. The business has a 50 day moving average price of $117.03 and a two-hundred day moving average price of $102.66. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The stock has a market capitalization of $5.08 billion, a P/E ratio of -17.38 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
